Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

AL102-503

12 evidence topics · 1 source

Objective
Location and study date
Registry status, dates, and sites
Study characteristicQuoted record
Protocol number“AL102-503”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-03-07”
Primary completion (actual)“2025-11-05”
Study completion (actual)“2026-03-06”
First posted“2025-02-24”
Last update posted“2026-03-10”
Sites“Orlando Clinical Research Center”; “The Texas Liver Institute”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“35”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
  • The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
  • The design is open label with a single oral dose, and the registry record does not state the dose.